CRRT的局部枸橼酸抗凝ppt课件

1、CRRT的部分枸橼酸抗凝的部分枸橼酸抗凝血透室血透室 方咏梅方咏梅ICU中的急性肾脏功能衰竭中的急性肾脏功能衰竭*: BEST Kidney患病率1738/29269 (5.7%, 95%CI 5.5 6.0%)危险要素感染性休克(47.5%, 95%CI 45.2 49.5%)住院病死率60.3% (95%CI 58.0 62.6%)*少尿( 84 mg/dL)Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter s

2、tudy. JAMA 2005; 294: 813-818急性肾功能衰竭的定义急性肾功能衰竭的定义: RIFLE规范规范GFR规范UO规范Risk肌酐添加x 1.5或GFR降低 25%UO 50%UO 75%UO 4周ESRD终末期肾病 3月Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Co

3、nsensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212ICU的急性肾脏损伤的急性肾脏损伤(AKI)Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35: 1837-184335.8%急性肾功能衰竭的治疗急性肾功能衰竭的治疗(n = 646)Perez-Valdivieso J

4、R, Bes-Rastrollo M, Monedero P, et al. Prognosis and serum creatinine levels in acute renal failure at the time of nephrology consultation: an observational cohort study. BMC Nephrology 2007; 8: 14-22继续肾脏替代治疗管路寿命继续肾脏替代治疗管路寿命满足治疗要求降低治疗费用减少重新安装管路的护理时间18 30 hrHolt AW, Bierer P, Glover P, Plummer JL, Be

5、rsten AD. Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits. Intensive Care Med 2002; 28: 1649-55.Stefanidis I, Hagel J, Frank D, Maurin N. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. Clin

6、Nephrol 1996; 46(3): 199-205.Kox WJ, Rohr U, Waurer H. Practical aspects of renal replacement therapy. Int J Artif Organs 1996; 19: 100-5.Tan HK, Baldwin I, Bellomo R. Continuous veno-venous haemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-7.继续肾脏替代治疗的影

7、响要素继续肾脏替代治疗的影响要素血管通路位置中心静脉导管: 口径, 管腔设计血流可靠性血滤管路设计透析膜的生物相容性护理人员的培训及专业技艺抗凝效果继续肾脏替代的抗凝继续肾脏替代的抗凝血滤滤器与管路的抗凝作用全身抗凝有害作用继续肾脏替代的抗凝选择继续肾脏替代的抗凝选择根底疾病现有抗凝措施临床阅历国内文献报告的抗凝方法国内文献报告的抗凝方法抗凝方法抗凝方法病例数病例数(%)单药抗凝普通肝素844 (37.9)低分子肝素686 (30.8)枸橼酸26 (1.2)结合抗凝普通肝素+低分子肝素483 (21.7)普通肝素+枸橼酸52 (2.3)无抗凝(6.1)CRRT时的肝素抗凝时的肝素抗凝出血危险负

8、荷剂量IU/kg维持剂量IU/kg/hrAPTTsecACTsec无危险性5010 2060 250危险较小15 255 1045160 180危险较大102.5 530120肝素抗凝的优缺陷肝素抗凝的优缺陷优点最常用的抗凝方法临床方案成熟半衰期短过量时鱼精蛋白对抗缺陷出血危险APTT与滤器寿命无关肝素诱导血小板缺乏(HIT)枸橼酸抗凝的原理枸橼酸抗凝的原理部分枸橼酸抗凝的原理部分枸橼酸抗凝的原理凝血过程需求游离钙参与枸橼酸螯合游离钙, 补充钙离子可以恢复血库运用枸橼酸保管血液采用枸橼酸可以在RRT时进展部分抗凝:血液进入体外循环后即参与枸橼酸血液进入体内前补充游离钙体外循环对血液进展抗凝,

9、体内血液正常经过测定游离钙监测抗凝肝素抗凝时的滤器中空纤维肝素抗凝时的滤器中空纤维Hofbauer R, Moser D, Frass M, et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int低分子肝素抗凝时的滤器中空纤维低分子肝素抗凝时的滤器中空纤维Hofbauer R, Moser D, Frass M, et al. Effect of anticoagulation on blood membrane interactions during hem

10、odialysis. Kidney Int枸橼酸抗凝时的滤器中空纤维枸橼酸抗凝时的滤器中空纤维Hofbauer R, Moser D, Frass M, et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int血滤终止的缘由血滤终止的缘由枸橼酸(n = 36)肝素(n = 43)管路凝血6 (16.7%)23 (53.5%)改为IHD1 (2.8%)0血管通路问题2 (5.6%)0管路断裂或渗漏1 (2.8%)0管路打折1 (2.8%)0转运至放射科或手术室8

11、(22.2%)8 (18.6%)滤器压力高1 (2.8%)2 (4.7%)其他缘由16 (44.4%)10 (23.3%)Kutsogiannis DJ, Gibney RTN, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367滤器寿命的滤器寿命的Cox风险比例模型分析风险比例模型分析HR95%CIP值枸橼酸0.3

12、710.197 0.6990.002LOD评分1.2671. 1.411 0.001女性0.5240.314 0.8740.01AT-III程度0.2140.065 0.7120.01Kutsogiannis DJ, Gibney RTN, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367出血或输血的比例出血或输血

13、的比例枸橼酸肝素相对危险度P值明确或隐性出血0.01 (0 0.04)0.13 (0.04 0.23)0.17 (0.03 1.04)0.06输注RBC0.17 (0.10 0.25)0.33 (0.18 0.49)0.53 (0.24 1.20)0.13输注FFP0.40 (0.29 0.52)0.08 (0.01 0.16)4.95 (0.47 52.3)0.18Kutsogiannis DJ, Gibney RTN, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continu

14、ous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367CRRT时出血的多要素时出血的多要素Poisson回归回归RR95%CIP值截距0.0010.00001 0.1740.008枸橼酸0.0.020 0.9590.05LOD评分0.9240.571 1.4940.75AT-III程度6.6470.789 56.0030.08Kutsogiannis DJ, Gibney RTN, Stollery D et al. Regional citrate versus systemic hep

15、arin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367不同抗凝方法的滤器寿命不同抗凝方法的滤器寿命Kutsogiannis DJ, Gibney RTN, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. K

16、idney Int 2005; 67: 2361-2367枸橼酸部分抗凝方案枸橼酸部分抗凝方案枸橼酸部分抗凝图示枸橼酸部分抗凝图示RheaterACD-AVVPVPAUFBLDSAD葡萄糖酸钙枸橼酸部分抗凝方案阐明枸橼酸部分抗凝方案阐明血滤机常规预冲肝素盐水根据患者病情选择适当治疗方式CVVHCVVHDCVVHDF枸橼酸部分抗凝方案枸橼酸部分抗凝方案预备枸橼酸抗凝液血液保管液(I) 600 ml/袋广州华南医疗用品成分成分分子量分子量含量含量(g)mmol枸橼酸三钠(二水)294.122.075枸橼酸(一水)210.148.038葡萄糖(一水)198.1724.5120加注射用水至1000 m

17、lRheaterACD-AVVPVPAUFBLDSAD葡萄糖酸钙枸橼酸部分抗凝方案枸橼酸部分抗凝方案预备输液泵将输液管路与血滤管路的动脉端相衔接最接近患者处(血泵前)根据患者病情, 设置血滤机的常规参数RheaterACD-AVVPVPAUFBLDSAD葡萄糖酸钙枸橼酸部分抗凝方案枸橼酸部分抗凝方案ACD-A初始泵速为血液流速(BFR)的2.0 2.5%泵速(ml/hr) = 1.2 1.5 x BFR (ml/min)例如BFR = 120 ml/minACD-A泵速 = 144 180 ml/hrRheaterACD-AVVPVPAUFBLDSAD葡萄糖酸钙枸橼酸部分抗凝方案枸橼酸部分抗凝

18、方案常规情况下选择前稀释方式RheaterACD-AVVPVPAUFBLDSAD葡萄糖酸钙枸橼酸部分抗凝方案枸橼酸部分抗凝方案置换液中不含钙RheaterACD-AVVPVPAUFBLDSAD葡萄糖酸钙常规置换液配方常规置换液配方0.9% NS2000 ml注射用水500 ml5% NaHCO3125 ml25% MgSO43 ml10% CaGlu20 ml15% KCl5 ml50% GS总量枸橼酸部分抗凝方案枸橼酸部分抗凝方案预备10%葡萄糖酸钙溶液及注射器泵将输液管路衔接至血滤管路静脉端葡萄糖酸钙溶液初始泵速为8.8 11.0 ml/hr (ACD-A泵速的6.1%)RheaterAC

19、D-AVVPVPAUFBLDSAD葡萄糖酸钙枸橼酸部分抗凝方案枸橼酸部分抗凝方案: 抗凝监测抗凝监测Q2h x 4Q4h x 4Day 1Day 2Q 6 8 h枸橼酸部分抗凝方案枸橼酸部分抗凝方案: 抗凝监测抗凝监测RheaterACD-AVVPVPAUFBLDSAD枸橼酸钙动脉标本动脉标本外周静脉或动脉外周静脉或动脉游离钙游离钙1.00 1.20 mmol/L静脉标本静脉标本滤器后血滤管路滤器后血滤管路游离钙游离钙0.20 0.40 mmol/L枸橼酸部分抗凝方案枸橼酸部分抗凝方案: 抗凝监测抗凝监测静脉标本游离钙静脉标本游离钙从滤器后静脉取血部位取血从滤器后静脉取血部位取血ACD-A输注速度调整输注速度调整 0.50 mmol/L添加10 ml/hr枸橼酸部分抗凝方案枸橼酸部分抗凝方案: 抗凝监测抗凝监测动脉标本游离钙动脉标本游离钙从外周静脉或动脉取血从外周静脉或动脉取血10%葡萄糖